Neurogene (NGNE) Stock Insights

NGNE price $30.49 +3.50 +12.95%

Ticker
NGNE
Price
$30.49
Change
+3.50 +12.95%
Market cap ?
$481.75M
Beta ?
2.09
Sector
Healthcare
Industry
Biotechnology

Fair value

NGNE fair value $104.80. Price $30.49. Price is 71% below fair value.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Calculated with a 10-year free-cash-flow discount. Starting free cash flow 254.46K. Growth 11.32%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 12.00% (beta 2.0). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 15.80M. Net debt -93.95M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.

Model uncertainty high for this stock

Compare NGNE

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-12—-1.49——
2026-08-11-1.53-1.42——
2026-05-12-1.39-1.30——
2026-03-24-1.12-1.24——
2025-11-14-0.99-1.26——
2025-08-11-1.05-1.15——
2025-05-09-1.08-1.05——
2025-03-24-0.99-1.04——
2024-11-18-1.19-1.22——
2024-08-09-1.09-1.05925.00K—
2024-05-09-1.00-1.13——
2024-03-18-1.51-1.17——
2023-11-14-2.47-0.60——
2023-08-10-0.21-0.80——
2023-05-08-5.20-4.40——
2023-03-20-4.80-3.80——
2022-11-14-4.80-6.09——
2022-08-09-5.60-6.00——
2022-05-09-5.60-5.96——

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-22McMinn RachelBuy756$25.3219.14K
2026-09-22McMinn RachelSell756$25.3219.14K
2026-07-07Cvijic Christine MikailSell4.20K$36.13151.76K
2026-07-06Cvijic Christine MikailSell600$36.0221.61K
2026-07-02Cvijic Christine MikailSell2.53K$34.5887.52K
2026-07-02Cvijic Christine MikailSell1.53K$35.2353.90K
2026-07-01Cvijic Christine MikailSell739$34.0625.17K
2026-05-06Cvijic Christine MikailSell4.80K$30.07144.35K
2026-05-06Cvijic Christine MikailSell4.80K$32.44155.69K
2026-05-05Shafer ChristinaBuy120.00K$28.943.47M
2026-04-20Shafer ChristinaOther0——
2026-03-26Cvijic Christine MikailSell2.56K$21.6255.32K
2026-03-26McMinn RachelSell3.35K$22.0774.00K
2026-03-26Jordan JulieSell828$21.8918.13K
2026-03-13Cobb StuartSell3.99K$20.4181.46K
2026-03-13Cobb StuartSell2.66K$21.3456.72K
2026-03-13Cobb StuartSell148$22.083.27K
2026-03-13Cvijic Christine MikailSell2.39K$20.4248.75K
2026-03-13Cvijic Christine MikailSell1.40K$21.2529.64K
2026-03-13Cvijic Christine MikailSell263$22.025.79K
2026-02-27Cvijic Christine MikailSell4.80K$25.11120.53K
2026-02-20Cobb StuartBuy16.50K——
2026-02-20Jordan JulieBuy29.60K$17.64522.14K
2026-02-20Jordan JulieBuy4.90K——
2026-02-20Cvijic Christine MikailBuy131.90K$17.642.33M
2026-02-20Cvijic Christine MikailBuy22.00K——
2026-02-20McMinn RachelBuy25.90K——
2026-02-20McMinn RachelBuy155.10K$17.642.74M
2026-02-20PALEKAR ROHANBuy12.05K$17.64212.56K
2026-02-20BAFFI ROBERTBuy12.05K$17.64212.56K
2026-02-20Noonberg Sarah B.Buy12.05K$17.64212.56K
2026-02-20Freedland Cory S.Buy12.05K$17.64212.56K
2026-02-20Woods KeithBuy12.05K$17.64212.56K
2025-06-12Woods KeithBuy12.05K$20.40245.82K
2025-06-12BAFFI ROBERTBuy12.05K$20.40245.82K
2025-06-12Woods Robert KeithBuy12.05K$20.40245.82K
2025-06-12PALEKAR ROHANBuy12.05K$20.40245.82K
2025-06-12Freedland Cory S.Buy12.05K$20.40245.82K
2025-06-12Noonberg Sarah B.Buy12.05K$20.40245.82K
2025-05-14Cobb StuartSell6.80K$15.15103.00K
2025-03-26Cobb StuartBuy42.90K$16.14692.41K
2025-03-26Cobb StuartBuy7.20K——
2025-03-26Cvijic Christine MikailBuy122.00K$16.141.97M
2025-03-26Cvijic Christine MikailBuy20.30K——
2025-03-26Jordan JulieBuy50.30K$16.14811.84K
2025-03-26Jordan JulieBuy8.40K——
2025-03-26McMinn RachelBuy23.90K——
2025-03-26McMinn RachelBuy143.50K$16.142.32M
2025-03-13Cvijic Christine MikailSell4.50K$16.9476.25K
2024-11-26Samsara BioCapital GP, LLCBuy2.00K$27.5055.00K
2024-11-26Samsara BioCapital GP, LLCBuy15.22K$26.73406.80K
2024-11-26Samsara BioCapital GP, LLCBuy10.80K$26.01280.99K
2024-11-26Samsara BioCapital GP, LLCBuy20.75K$24.91516.83K
2024-11-25Samsara BioCapital GP, LLCOther0——
2024-11-25Samsara BioCapital GP, LLCOther67.07K——
2024-11-25Samsara BioCapital GP, LLCOther20.00K$0.0020
2024-11-22Cvijic Christine MikailBuy24.00K$20.48491.40K
2024-11-22McMinn RachelBuy47.50K$20.40969.00K
2024-06-14Woods KeithBuy7.70K$42.59327.94K
2024-06-14Woods Robert KeithBuy7.70K$42.59327.94K
2024-06-14PALEKAR ROHANBuy7.70K$42.59327.94K
2024-06-14BAFFI ROBERTBuy7.70K$42.59327.94K
2024-06-14Noonberg Sarah B.Buy7.70K$42.59327.94K
2024-06-14Freedland Cory S.Buy7.70K$42.59327.94K
2024-03-13McMinn RachelBuy93.28K$36.063.36M
2024-03-13Cvijic Christine MikailBuy53.90K$36.061.94M
2024-03-13Cvijic Christine MikailBuy31.90K——
2024-03-13Cobb StuartBuy34.45K$36.061.24M
2024-03-13Cobb StuartBuy20.39K——
2024-01-16Woods KeithBuy15.40K$32.30497.42K
2023-12-18Woods KeithOther0——
2023-12-18BAKER BROS. ADVISORS LPBuy1.15M——
2023-12-18BAKER BROS. ADVISORS LPBuy221.56K——
2023-12-18BAKER BROS. ADVISORS LPBuy310.13K——
2023-12-18BAKER BROS. ADVISORS LPBuy973.29K——
2023-12-18BAKER BROS. ADVISORS LPBuy93.48K——
2023-12-18BAKER BROS. ADVISORS LPBuy20.56K——
2023-12-18BAKER BROS. ADVISORS LPBuy28.78K——
2023-12-18BAKER BROS. ADVISORS LPBuy78.33K——

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 117, holders +16 vs prior quarter. Ownership 76.92%.

HolderSharesChangeChange %Value
SAMSARA BIOCAPITAL, LLC1.72M00.00%54.00M
CASDIN CAPITAL, LLC1.55M125.00K+8.80%48.60M
REDMILE GROUP, LLC1.41M-47.40K-3.25%44.41M
RTW INVESTMENTS, LP1.36M00.00%42.85M
ECOR1 CAPITAL, LLC1.27M00.00%39.98M
BLACKROCK, INC.1.06M52.91K+5.26%33.27M
BAKER BROS. ADVISORS LP991.69K00.00%31.19M
BALYASNY ASSET MANAGEMENT L.P.818.71K100.32K+13.96%25.75M
TRAILS EDGE CAPITAL PARTNERS, LP714.88K-67.90K-8.67%22.48M
TORONTO DOMINION BANK681.34K00.00%21.43M
VANGUARD CAPITAL MANAGEMENT LLC536.52K21.80K+4.23%16.87M
JENNISON ASSOCIATES LLC518.58K-9.10K-1.73%16.31M
CITADEL ADVISORS LLC408.98K397.88K+3584.52%12.86M
GREAT POINT PARTNERS LLC352.18K-147.82K-29.56%11.08M
ARROWMARK COLORADO HOLDINGS LLC342.45K-182.34K-34.75%10.77M
FMR LLC295.56K-87.09K-22.76%9.30M
GEODE CAPITAL MANAGEMENT, LLC293.18K14.18K+5.08%9.22M
STATE STREET CORP224.32K-88.68K-28.33%7.05M
FRANKLIN TEMPLETON INC204.28K204.28KNew6.42M
MORGAN STANLEY191.72K-93.52K-32.78%6.03M
UBS GROUP AG171.29K-14.39K-7.75%5.39M
BLAIR WILLIAM & CO/IL146.91K-21.31K-12.67%4.62M
DRIEHAUS CAPITAL MANAGEMENT LLC143.53K110.76K+338.05%4.51M
POINT72 ASSET MANAGEMENT, L.P.141.92K141.92KNew4.46M
MOORE CAPITAL MANAGEMENT, LP141.64K141.64KNew4.45M

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Neurogene (NGNE) Stock Insights

NGNE$30.49+3.50 +12.95%

$481.75M

Market Cap

—

P/E

—

Forward P/E

—

Score

Price History